Elderly people who or those having underlying diseases like high blood pressure and diabetes may be at a higher risk of death from novel coronavirus (COVID-19).
This has been deduced through a study which got published in The Lancet journal.
Ready for a challenge? Click here to take our quiz and show off your knowledge!
The observational study was carried on 191 patients with confirmed COVID-19 from two hospitals in Wuhan of China.
The study is the first time researchers have examined risk factors associated with severe disease and death in hospitalized adults who have either died or been discharged from hospital.
Also read: Coronavirus cases rise to 73 in India
Ready for a challenge? Click here to take our quiz and show off your knowledge!
This may be because of age-related weakening of the immune system and increased inflammation that could promote viral replication and more prolonged responses to inflammation, causing lasting damage to the heart, brain, and other organs.
In the study of 191 patients, 137 were discharged and 54 died in hospital.
However, the researchers noted that interpretation of their findings might be limited by the study’s sample size.
They presented new data on viral shedding, which indicates that the median duration of viral shedding was 20 days in survivors (ranging from 8 to 37 days), and the virus was detectable until death in the 54 non-survivors.
While prolonged viral shedding suggests that patients may still be capable of spreading COVID-19, the researchers caution that the duration of viral shedding is influenced by disease severity.
They noted that all patients in the study were hospitalized, two-thirds of whom had severe or critical illness.
The researchers recommended that negative tests for COVID-19 should be required before patients are discharged from hospital.
In severe influenza, delayed viral treatment extends how long the virus is shed, and together these factors put infected patients at risk of dying, they said.
The researchers noted that effective antiviral treatment may improve outcomes in COVID-19, although they did not observe shortening of viral shedding duration after antiviral treatment in the study.
For the first time, the study describes the complete picture of the progression of the COVID-19.
The median duration of fever was about 12 days in survivors, which was similar in non-survivors.
However, the cough may last for a long time – 45 per cent of survivors still had cough on discharge, the study found.
In survivors, dyspnoea (shortness of breath) would cease after about 13 days, but would last until death in non-survivors.
The study also illustrates the time of the occurrence of different complications such as sepsis, acute respiratory distress syndrome (ARDS), acute cardiac injury, acute kidney injury and the secondary infection.